<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H5694DBBB2A264A8FAED5FA4A62FC22E3" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1485 IH: Insulin for All Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1485</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230309">March 9, 2023</action-date><action-desc><sponsor name-id="B001224">Ms. Bush</sponsor> (for herself, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="G000587">Ms. Garcia of Texas</cosponsor>, <cosponsor name-id="T000481">Ms. Tlaib</cosponsor>, <cosponsor name-id="O000172">Ms. Ocasio-Cortez</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="B001223">Mr. Bowman</cosponsor>, <cosponsor name-id="G000553">Mr. Green of Texas</cosponsor>, <cosponsor name-id="P000617">Ms. Pressley</cosponsor>, <cosponsor name-id="G000586">Mr. Garc√≠a of Illinois</cosponsor>, <cosponsor name-id="J000298">Ms. Jayapal</cosponsor>, <cosponsor name-id="K000389">Mr. Khanna</cosponsor>, <cosponsor name-id="P000604">Mr. Payne</cosponsor>, and <cosponsor name-id="O000173">Ms. Omar</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To limit the price charged by manufacturers for insulin.</official-title></form><legis-body id="HD6723D029EA540AC9A67B256C38F8E7C" style="OLC"><section id="H61FA749E060B47579CCA1635C3E36170" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Insulin for All Act of 2023</short-title></quote>.</text></section><section id="H6891A7FC7773423989860242F32ECBF8"><enum>2.</enum><header>Limitation on price of insulin</header><subsection commented="no" display-inline="no-display-inline" id="H999CFB0DA1E946048BAD451F4DC7ED27"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Notwithstanding any other provision of law, the price charged by manufacturers of insulin for insulin that is sold in the United States may not exceed $20 per 1000 units of insulin, which may be contained in one or more vials, pens, cartridges, or other forms of delivery.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="H03510EFF0B644E4C8CC6EAF662740A7E"><enum>(b)</enum><header>Insulin defined</header><text>In this section, the term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and continues to be marketed pursuant to such licensure.</text></subsection></section></legis-body></bill> 

